School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, 730000, China; Gansu Province Key Laboratory of Chinese Medicine for the Prevention andTreatment of Chronic Diseases, Lanzhou, 730000, China; Key clinical specialty of the National Health Commission of the People's Republic of China, Key Specialized Cardiovascular Laboratory National Administration of Traditional Chinese Medicine, Lanzhou, 730000, China.
Gansu Province Key Laboratory of Chinese Medicine for the Prevention andTreatment of Chronic Diseases, Lanzhou, 730000, China; Key clinical specialty of the National Health Commission of the People's Republic of China, Key Specialized Cardiovascular Laboratory National Administration of Traditional Chinese Medicine, Lanzhou, 730000, China; Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou, 730000, China.
J Ethnopharmacol. 2023 Apr 6;305:116128. doi: 10.1016/j.jep.2022.116128. Epub 2023 Jan 6.
Myocardial fibrosis (MF) is a common pathological manifestation of many cardiovascular diseases at a certain stage, with excessive accumulation of collagen fibers, excessive increase in collagen content, and a significant increase in collagen volume as the main pathological changes. There are currently no effective drugs for the treatment of myocardial fibrosis. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years, especially in China, often exerts a wider action spectrum than previously attempted options in treating human diseases. In recent times, the great potential of TCM in the treatment of MF has received much attention. Especially many experimental studies on the treatment of MF by Astragalus mongholicus Bunge have been conducted, and the effect is remarkable, which may provide more comprehensive database and theoretical support for the application of Astragalus mongholicus Bunge in the treatment of MF and could be considered a promising candidate drug for preventing MF.
This review summarizes the chemical components of Astragalus mongholicus Bunge, Astragalus mongholicus Bunge extract, Astragalus mongholicus Bunge single prescription, and Astragalus mongholicus Bunge compound preparation in the treatment of MF, and provides comprehensive information and a reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of MF.
The literature information was obtained from the scientific databases on ethnobotany and ethnomedicines (up to August 2022), mainly from the PubMed, Web of Science, and CNKI databases. The experimental studies on the anti-myocardial fibrosis role of the effective active components of Astragalus mongholicus Bunge and the utility of its compound preparation and the involved mechanisms were identified. The search keywords for such work included: "myocardial fibrosis" or "Cardiac fibrosis ", and "Astragalus mongholicus Bunge", "extract," or "herb".
Several studies have shown that the effective active components of Astragalus mongholicus Bunge and its formulas, particularly Astragaloside IV, Astragalus polysaccharide, total saponins of Astragalus mongholicus Bunge, triterpenoid saponins of Astragalus mongholicus Bunge, and cycloastragenol, exhibit potential benefits against MF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc. Conclusion: These research works have shown the therapeutic benefits of Astragalus mongholicus Bunge in the treatment of MF. However, further research should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights in the present review provided rich ideas for developing new anti-MF drugs.
Myocardial fibrosis (MF) with excessive accumulation of collagen fibers, excessive increase in collagen content, and a significant increase in collagen volume as the main pathological changes is a common pathological manifestation of many cardiovascular diseases at a certain stage, which seriously affects cardiac function. At present, there is still a lack of effective drugs for the treatment of MF. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. In recent times, the great potential of TCM in the treatment of MF has received much attention. Especially many experimental studies on the treatment of MF by Astragalus mongholicus Bunge have been conducted, and the effect is remarkable, which may provide more comprehensive data base and theoretical support for the application of Astragalus mongholicus Bunge in the treatment of MF and could be considered a promising candidate drug for preventing MF.
心肌纤维化（MF）是许多心血管疾病在一定阶段的常见病理表现，以胶原纤维过度堆积、胶原含量过度增加和胶原体积显著增加为主要病理变化。目前，治疗心肌纤维化的有效药物仍然缺乏。中医（TCM），是一种有 5000 多年历史的医学实践的主要组成部分，尤其是在中国，在治疗人类疾病方面往往比以前尝试的方法具有更广泛的作用范围。最近，TCM 在治疗 MF 方面的巨大潜力引起了广泛关注。特别是对蒙古黄芪治疗 MF 的许多实验研究已经进行，效果显著，这可能为蒙古黄芪在 MF 治疗中的应用提供更全面的数据库和理论支持，并可能被认为是预防 MF 的有前途的候选药物。
本综述总结了蒙古黄芪的化学成分、蒙古黄芪提取物、蒙古黄芪单方和蒙古黄芪复方制剂在治疗 MF 中的作用，为植物药治疗 MF 的新治疗策略探索提供了全面的信息和可靠的依据。
文献信息来自民族植物学和民族医学的科学数据库（截至 2022 年 8 月），主要来自 PubMed、Web of Science 和中国知网数据库。确定了蒙古黄芪有效活性成分及其复方制剂抗心肌纤维化作用及其涉及的机制的实验研究。此类工作的搜索关键词包括：“心肌纤维化”或“Cardiac fibrosis”，以及“蒙古黄芪”、“提取物”或“草药”。
几项研究表明，蒙古黄芪的有效活性成分及其配方，特别是黄芪甲苷、黄芪多糖、蒙古黄芪总皂苷、蒙古黄芪三萜皂苷和环黄芪醇，对 MF 具有潜在的益处，其机制似乎涉及炎症、氧化应激和促纤维化信号通路的调节等。
这些研究工作表明蒙古黄芪在 MF 治疗中的治疗益处。然而，仍需要进一步研究以阐明不确定的化学成分和调节机制，进行标准的临床试验，并评估可能的副作用。本综述中的见解为开发新的抗 MF 药物提供了丰富的思路。
